Nebenwirkungen · Ongentys
Ongentys 25 mg hard capsules Ongentys 50 mg hard capsules · Abschnitt 4.8 · PDF-Seite 6
HOS-129718 · Präparat HOS-096787
Table 1 – Frequency of adverse reactions (MedDRA) in placebo-controlled Phase 3 studies System Organ Class Very common Common Uncommon Metabolism and Decreased appetite, nutrition disorders Hypertriglyceridaemia Psychiatric disorders Abnormal dreams, Anxiety, Hallucination, Depression, Hallucination visual, Hallucination auditory, Insomnia Confusional state, Nightmare, Sleep disorder Nervous system Dyskinesia Dizziness, Dysgeusia, disorders Headache, Hyperkinesia, Somnolence Syncope Eye disorders Dry eye Ear and labyrinth Ear congestion disorders Cardiac disorders Palpitations Vascular disorders Orthostatic Hypertension, Hypotension Hypotension Respiratory, thoracic Dyspnoea and mediastinal disorders Gastrointestinal Constipation, Abdominal distention, disorders Dry mouth, Abdominal pain, Nausea, Abdominal pain upper, Vomiting Dyspepsia Musculoskeletal and Muscle spasms Muscle twitching, connective tissue Musculoskeletal disorders stiffness, Myalgia, Pain in extremity Renal and urinary Chromaturia, disorders Nocturia General disorders and Fatigue administration site conditions Investigations Blood creatine Weight decreased phosphokinase increased
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-07T10:00:00Z · SHA-256 5440c5fa9668dadbdfe2b487d148f72232f8fdbfa654e4a6492429ca5c3f530f · Passage 11e05de5864dc0aaa4afe161e1631241191e713c2199016692de5831e2abd967 · Zeichen 576–3455 im Abschnitt